Allogene Therapeutics, Inc.
NASDAQ:ALLOBiotechnology
Healthcare
$0.70 +1.02%
+$0.02 today
- Market cap
- $241.11M
- Beta
- 0.46
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.72
52W Low $0.98High $4.46
Volume 10.55M
Average 10.19M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$206.93M
FY 2025 · Annual
Net Income
-$190.89M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 114.09M | 156K | 95K | 22K | 0 |
| Cost of Revenue | 0 | 14.3M | 0 | 0 | 12.36M |
| Gross Profit | 114.09M | (14.14M) | 95K | 22K | (12.36M) |
| Gross Margin | 100.0% | -9063.5% | 100.0% | 100.0% | — |
| Research & Development | 220.18M | 256.39M | 242.91M | 192.3M | 150.15M |
| Selling, General & Admin | 74.11M | 79.31M | 71.67M | 65.21M | 56.78M |
| Operating Expenses | 294.28M | 321.4M | 327.83M | 273.22M | 194.57M |
| Depreciation & Amortization | 10.45M | 14.3M | 14.2M | 13.64M | 12.36M |
| EBITDA | (171.6M) | (326.12M) | (313.07M) | (243.33M) | (177.45M) |
| EBITDA Margin | -150.4% | -209050.6% | -329543.2% | -1106031.8% | — |
| Operating Income | (180.19M) | (335.54M) | (327.74M) | (273.2M) | (206.93M) |
| Operating Margin | -157.9% | -215087.2% | -344986.3% | -1241813.6% | — |
| Interest Income | 1.71M | 4.57M | 18.31M | 20.15M | 19.29M |
| Interest Expense | 0 | 0 | 0 | 181K | 1.08M |
| Other Income / Expenses | (1.86M) | (4.88M) | 472K | 16.05M | 16.05M |
| Income Before Tax | (182.05M) | (340.41M) | (327.27M) | (257.15M) | (190.89M) |
| Pre-Tax Margin | -159.6% | -218214.1% | -344489.5% | -1168850.0% | — |
| Income Tax Expense | 0 | 0 | 0 | 443K | 0 |
| Net Income | (182.05M) | (340.41M) | (327.27M) | (257.59M) | (190.89M) |
| Net Margin | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
| EPS (Basic) | (1.34) | (2.38) | (2.09) | (1.32) | (0.87) |
| EPS (Diluted) | (1.34) | (2.38) | (2.09) | (1.32) | (0.87) |
| 135.82M | 143.15M | 156.93M | 194.81M | 220.62M | |
| 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
ALLO Earnings Waterfall · TTM
NASDAQ:ALLO · Revenue to Net Income
Key Ratios
EPS$-0.77
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.1
P/S Ratio0.0
Analysis
$0 of revenue converted into -$173.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.77, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 23, 2026 |
How much revenue does ALLO generate?
Allogene Therapeutics, Inc. (ALLO) reported $0.00 of revenue in fiscal 2025.
Is ALLO profitable?
Allogene Therapeutics, Inc. (ALLO) reported -$190.89M of net income.
Continue the stock analysis
Jump to another research area for this company.